Tecentriq 840mg injection is an anticancer medication containing the active ingredient Atezolizumab which belongs to the class of medicine called monoclonal antibody (Mab). It is indicated to treat cancer in the bladder, lungs, liver, and breast. Mab is a type of protein, to get attached to a specific target in the body. This antibody helps the immune system to fight against cancer. This medicine is used as adjuvant therapy (treatment after surgery) for lung cancer conditions where the cancer is not spread to other body parts. It is either used alone or with a combination of other anticancer medicine. 

Do not take a Tecentriq 840mg injection if you are allergic to Atezolizumab or other medicine ingredients. This medicine is not recommended for children and adolescents. Notify your healthcare professional if you experience any symptoms like inflammation of the lung, liver, intestine, thyroid, adrenal glands, and pituitary gland; your doctor might prescribe other medications to prevent complications and reduce the symptoms. 

Before takingTecentriq 840mg, inform your doctor if you have or ever had an autoimmune disease (the body attacks its cells), HIV infection or AIDS, past with pneumonitis (inflammation of the lung), infections like HIV/AIDS, a chronic viral infection of the liver (hepatitis B / hepatitis C). Also, notify if you have been given any live, attenuated vaccine, antibiotic within the two weeks, or any medicine to improve or suppress your immune system. Report your doctor if you are pregnant or planning to get pregnant. Use effective birth control during and even after the treatment for five months. 

• Urothelial carcinoma

• Non-small cell lung cancer

• small cell lung cancer

• Triple-negative breast cancer

• Hepatocellular carcinoma

Tecentriq 840mg is a monoclonal antibody that blocks the interaction between PD-L1 and PD-1, which can help the T-cells recognize and attack cancer cells more effectively. By doing so, Tecentriq 840mg can stimulate the immune system to attack cancer cells and potentially slow down or stop cancer growth.

Inform your healthcare provider about all the medicines you take, including prescription, over-the-counter, nutritional, supplements, and herbal products. In particular, tell your doctor if you are taking medicines for blood pressure or other heart conditions. Certain medications may interact with Tecentriq 840mg and reduce its effectiveness by causing undesirable side effects. 

• Store Tecentriq 840mg in the refrigerator (2°C to 8°C)
• Do not freeze
• keep the injection away from the reach of children and pets.
• If you have missed any dosing appointments, inform your doctor and schedule immediately.

A trained doctor or nurse should only administer it. Do not self-administer the injection. Your doctor will decide the dose and duration of your treatment based on the disease severity and other factors. It will be given as an intravenous infusion, and you will be monitored carefully for unwanted side effects. The first infusion will take around 60 minutes and must be monitored carefully. If there is no infusion reaction for the first dose, the next infusion will last 30 minutes. 

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.

Serious

• Inflammation (lung, liver, intestine, thyroid, adrenal glands, and pituitary gland)
• Type 1 diabetes
• Inflammation of the brain, heart muscle, kidney, muscle
• Severe skin reaction
• Inflammation of problem with nerve

Common

• Fever
• Loss of appetite
• Urinary tract infection
• Pain in the joints, muscles, and bones
• Headache
• Hair loss
• Numbness in hands and feet
• Sensitivity to sun
• Constipation
• Low oxygen level
• High blood sugar
• Pain in stomach, mouth, and throat

Notify our doctor if you are taking or have recently taken any other medications. Before starting the treatment, it is advised to have a blood test and general health check-up. Report to your doctor if you experience any side effects; your doctor may delay. This medicine is not recommended for children and adolescents under 18 years. Before starting the treatment, inform your doctor if your cancer cell has spread to the brain. 

1. Roche, Electronic Medicines Compendium (EMC) [Revised on Feb 2022], [Accessed on 25th April 2023],  Tecentriq 1,200 mg concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc) (medicines.org.uk)
2. Genentech Inc, US Food and Drug Administration [Revised on Oct 2021] [Accessed on 25th April 2023],  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf
3. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman's Pharmacological